Verge Genomics

Excited for Biocom California’s sold-out Bay Area CEO Summit on October 24, where Alice Zhang will be participating in the session, CEO Perspectives. #BiocomCEOSummit

Our Chief Medical Officer, Dr. Cadavid, will be presenting at the Pharmaceutical and Bioscience Society International (PBSS) Virtual Conference on Emerging Biology and Therapeutics. He'll be sharing insights on Verge’s innovative proof-of-concept study of VRG50468, a PIKfyve inhibitor, for the treatment of ALS. Registration is required via: pbss.org/login #ALS #PBSS2025 #ClinicalResearch

We’re proud to share that our Chief Medical Officer, Dr. Diego Cadavid, will present two posters at the upcoming @ENCALS 2025 meeting in Torino, Italy, June 3 - 6. These presentations highlight our latest advances in ALS research - deepening scientific understanding and supporting the development of novel, brain-penetrant therapies. #ALSresearch #DigitalBiomarkers #ClinicalResearch

Today we announced "Verge Genomics and Collaborators Identify Digital Clinical Biomarker Endpoints Sensitive to Short Term Disease Progression in the Pre-treatment Run-in Period of VRG50635 Proof-of-Concept ALS Clinical Trial". Our CMO, Diego Cadavid, will be presenting new findings tomorrow at the AAN 2025. For more details: businesswire.com/news/home/2025…

We are thrilled that Verge Genomics' CMO, Diego Cadavid, will be presenting at the 77th Annual Meeting of the American Academy of Neurology (AAN) in San Diego on Tuesday, April 8, 2025! #AAN2025 #ALS #Clinicaltrial

We are thrilled to share that our Head of Drug Discovery, Irene Choi, PhD, will be presenting at the upcoming Keystone Symposia on MASH Pathogenesis and Therapeutic Approaches! She will be discussing some of our exciting findings on the role of CD38 in reducing weight gain in mice fed a high-fat diet. Please stop by and see Irene at poster number 2520. #KSMASH25 #drugdiscovery #therapeuticapproaches

Today, we announced the nomination of our 2nd development candidate. VRG201, a first-in-class oral small molecule targeting CD38, aims to correct the underlying metabolic dysfunction leading to obesity and help patients sustain weight loss. Learn more: globenewswire.com/news-release/2…

Verge Genomics’ CEO, @AliceXinliZhang, is speaking at the #ForbesHealth Summit, tomorrow 12/4. She’ll join a panel on “Advancements in Drug Discovery” to discuss innovation in #AI-powered medicine. Thank you @Forbes for having us.

Today, we announced a significant milestone in our collaboration with @EliLillyandCo. Lilly has opted to pursue the development of therapeutics against two validated drug targets for ALS identified and validated by our AI-enabled CONVERGE® platform. Read more: bit.ly/3Z4Q3VM

Betting Big on Bio! @SXSW Sydney! Verge's Alice Zhang will join biotech experts to discuss its transformative power & how it'll shape our future at #SXSWSydney. More info: tinyurl.com/2xn4khxw

Our CEO Alice Zhang is honored to be a keynote speaker at the Longevity Platinum Trip, where she'll share how Verge is enhancing health-spans through CONVERGE®, our AI-driven drug discovery and development platform. #AI #DrugDiscovery #Healthspan #Biotech

If you are at #ANA2024 next week don’t miss Verge CMO Diego Cadavid’s presentation on our PIKfyve Inhibitor VRG50635 a potential treatment for #ALS and one of the first drugs discovered & developed from an #AI-powered platform to go to clinic

Join @VergeGenomic's Diego Cadavid at #ENCALS24 in Stockholm next week! He'll share an update on Verge's unique Proof of Concept Study on VRG50635, a potential treatment for all forms of ALS. #ALS #ENCALS #AIDrugDiscovery

We are thrilled to share an insightful article by our CEO, @AliceZhang, featured in Fortune. Alice's perspective on leading with empathy, embracing vulnerability, and fostering transparency and trust is integral to Verge's mission tinyurl.com/bdhxvwcm

Meet the @VergeGenomics BD Team, Michelle Mighdoll & Sam Galindo, at #BIO2024! Looking forward to connect and collaborate June 3-6, 2024. #BIO2024 #AI

Don’t miss Verge's Irene Choi at #DiscoveryEurope24 for insights on how CONVERGE identifies novel targets, our proof-of-concept ALS study that was discovered using CONVERGE® and the future of AI/ML in drug discovery and beyond! Details below.  #AI #DrugDiscovery

Verge @DiegoCadavid is presenting at the 3rd Annual #ALS Drug Dev Summit on 5/23, 11:30  where he'll discuss Verge's groundbreaking proof-of-concept study for VRG50635, a potential new ALS treatment. Don't miss it! #ALSresearch #VRG50635 ter.li/qdfuop